Ting Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ting Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Chengshi Quan
The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical College, Jilin University, Changchun, Jilin, China
1 shared publication- Chengshi Quan
The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, Jilin 130021, China
1 shared publication Huiying Jin
Department of Pathology, Jilin Oil Field General Hospital, Songyuan, Jilin, China
1 shared publicationLi Liu
Department of Pathology, Jilin Oil Field General Hospital, Songyuan, Jilin, China
1 shared publicationLina Yu
The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical College, Jilin University, Changchun, Jilin, China
1 shared publication- Minlan Yang
Department of Pathology, School of Medicine, Yangtze University, Jingzhou, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2017
- Published by MDPI AG in Preprints.org
Screening for Target Genes of CLDN6 in Breast Cancer Cell Line MCF-7 using Microarray Technology
Claudin-6 (CLDN6), one of CLDNs family which as the important component of tight junctions (TJs). CLDN6 function as a tumor suppressor in breast cancer as we declared before, whereas the molecular mechanism of CLDN6 on suppressing malignant phenotype of breast cancer is unclear. Gene expression profiling was used to investigate target genes of CLDN6 and the mechanism involved in malignant phenotypes of breast cancer cell line MCF-7. In three clones of CLDN6 over-expressed MCF-7 cells (MCF-7(CLDN6)), 54 up-regulated and 24 down-regulated genes were detected. Gene Ontology (GO) analysis revealed that differential expressed genes in MCF-7(CLDN6) clones mainly located on the membrane and nucleus, involved in metabolic processes, biological regulation, protein binding and cell communication. KEGG pathway enrichment analysis revealed that among the target genes and related pathways, three MCF-7(CLDN6) clones co-upregulated gene Stat4 and the other members of Jak/Stats signal pathway (Tyk2, Stat1, Stat3, Stat5a, Stat5b and Stat6) were up-regulated in the other two of MCF-7(CLDN6) clones, which have been participate in the signal transduction pathway in cancer. MTT assay, wound healing assay and invasion assay showed that inhibiting the Tyk2/Stats signal pathway with the tyrosine kinase inhibitor AG490 partially reversed the effect of CLDN6 on proliferation, migration and invasion of MCF-7 cells, besides, AG490 reversed expressions of EMT markers when CLDN6 overexpression brought, the data confirmed that, under the effect of high flux, gene expression profiling can be used as a means to study genes affected by CLDN6, and to screen the key regulatory genes involved in breast cancer.
- 17 July 2017
- Published by MDPI AG in Preprints.org
Open AccessScreening for Target Genes of CLDN6 in Breast Cancer Cell Line MCF-7 using Microarray Technology
Claudin-6 (CLDN6), one of CLDNs family which as the important component of tight junctions (TJs). CLDN6 function as a tumor suppressor in breast cancer as we declared before, whereas the molecular mechanism of CLDN6 on suppressing malignant phenotype of breast cancer is unclear. Gene expression profiling was used to investigate target genes of CLDN6 and the mechanism involved in malignant phenotypes of breast cancer cell line MCF-7. In three clones of CLDN6 over-expressed MCF-7 cells (MCF-7(CLDN6)), 54 up-regulated and 24 down-regulated genes were detected. Gene Ontology (GO) analysis revealed that differential expressed genes in MCF-7(CLDN6) clones mainly located on the membrane and nucleus, involved in metabolic processes, biological regulation, protein binding and cell communication. KEGG pathway enrichment analysis revealed that among the target genes and related pathways, three MCF-7(CLDN6) clones co-upregulated gene Stat4 and the other members of Jak/Stats signal pathway (Tyk2, Stat1, Stat3, Stat5a, Stat5b and Stat6) were up-regulated in the other two of MCF-7(CLDN6) clones, which have been participate in the signal transduction pathway in cancer. MTT assay, wound healing assay and invasion assay showed that inhibiting the Tyk2/Stats signal pathway with the tyrosine kinase inhibitor AG490 partially reversed the effect of CLDN6 on proliferation, migration and invasion of MCF-7 cells, besides, AG490 reversed expressions of EMT markers when CLDN6 overexpression brought, the data confirmed that, under the effect of high flux, gene expression profiling can be used as a means to study genes affected by CLDN6, and to screen the key regulatory genes involved in breast cancer.
- Open Access
- 29 March 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 33
The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas
Background: Claudin-6 is a candidate tumor suppressor gene in breast cancer, and has been shown to be regulated by DNA methylation and histone modification in breast cancer lines. However, the expression of claudin-6 in breast invasive ductal carcinomas and correlation with clinical behavior or expression of other markers is unclear. We considered that the expression pattern of claudin-6 might be related to the expression of DNA methylation associated proteins (methyl-CpG binding protein 2 (MeCP2) and DNA methyltransferase 1 (DNMT1)) and histone modification associated proteins (histone deacetylase 1 (HDAC1), acetyl-histone H3 (H3Ac) and acetyl- histone H4 (H4Ac)).Methods: We have investigated the expression of claudin-6, MeCP2, HDAC1, H3Ac and H4Ac in 100 breast invasive ductal carcinoma tissues and 22 mammary gland fibroadenoma tissues using immunohistochemistry.Results: Claudin-6 protein expression was reduced in breast invasive ductal carcinomas (P< 0.001). In contrast, expression of MeCP2 (P< 0.001), DNMT1 (P= 0.001), HDAC1 (P< 0.001) and H3Ac (P= 0.004) expressions was increased. Claudin-6 expression was inversely correlated with lymph node metastasis (P= 0.021). Increased expression of HDAC1 was correlated with histological grade (P< 0.001), age (P= 0.004), clinical stage (P= 0.007) and lymph node metastasis (P= 0.001). H3Ac expression was associated with tumor size (P= 0.044) and clinical stage of cancers (P= 0.034). MeCP2, DNMT1 and H4Ac expression levels did not correlate with any of the tested clinicopathological parameters (P> 0.05). We identified a positive correlation between MeCP2 protein expression and H3Ac and H4Ac protein expression.Conclusions: Our results show that claudin-6 protein is significantly down-regulated in breast invasive ductal carcinomas and is an important correlate with lymphatic metastasis, but claudin-6 down-regulation was not correlated with upregulation of the methylation associated proteins (MeCP2, DNMT1) or histone modification associated proteins (HDAC1, H3Ac, H4Ac). Interestingly, the expression of MeCP2 was positively correlated with the expression of H3Ac and H3Ac protein expression was positively correlated with the expression of H4Ac in breast invasive ductal carcinomaVirtual slides: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/4549669866581452
- 29 March 2012
- Published by Springer Nature in Diagnostic Pathology
- Vol. 7 (1) , 33
Open AccessThe expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas
Background: Claudin-6 is a candidate tumor suppressor gene in breast cancer, and has been shown to be regulated by DNA methylation and histone modification in breast cancer lines. However, the expression of claudin-6 in breast invasive ductal carcinomas and correlation with clinical behavior or expression of other markers is unclear. We considered that the expression pattern of claudin-6 might be related to the expression of DNA methylation associated proteins (methyl-CpG binding protein 2 (MeCP2) and DNA methyltransferase 1 (DNMT1)) and histone modification associated proteins (histone deacetylase 1 (HDAC1), acetyl-histone H3 (H3Ac) and acetyl- histone H4 (H4Ac)).Methods: We have investigated the expression of claudin-6, MeCP2, HDAC1, H3Ac and H4Ac in 100 breast invasive ductal carcinoma tissues and 22 mammary gland fibroadenoma tissues using immunohistochemistry.Results: Claudin-6 protein expression was reduced in breast invasive ductal carcinomas (P< 0.001). In contrast, expression of MeCP2 (P< 0.001), DNMT1 (P= 0.001), HDAC1 (P< 0.001) and H3Ac (P= 0.004) expressions was increased. Claudin-6 expression was inversely correlated with lymph node metastasis (P= 0.021). Increased expression of HDAC1 was correlated with histological grade (P< 0.001), age (P= 0.004), clinical stage (P= 0.007) and lymph node metastasis (P= 0.001). H3Ac expression was associated with tumor size (P= 0.044) and clinical stage of cancers (P= 0.034). MeCP2, DNMT1 and H4Ac expression levels did not correlate with any of the tested clinicopathological parameters (P> 0.05). We identified a positive correlation between MeCP2 protein expression and H3Ac and H4Ac protein expression.Conclusions: Our results show that claudin-6 protein is significantly down-regulated in breast invasive ductal carcinomas and is an important correlate with lymphatic metastasis, but claudin-6 down-regulation was not correlated with upregulation of the methylation associated proteins (MeCP2, DNMT1) or histone modification associated proteins (HDAC1, H3Ac, H4Ac). Interestingly, the expression of MeCP2 was positively correlated with the expression of H3Ac and H3Ac protein expression was positively correlated with the expression of H4Ac in breast invasive ductal carcinomaVirtual slides: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/4549669866581452